We know development. Here is what our scientists think about it.
The Cheapest Quote Is Not Always the Cheapest Programme When a biotech company evaluates its outsourcing options, the instinct is often to find the best vendor for each individual piece of work. The best formulation house for development, the best API lab for synthesis, the best analytical CRO for method validation, and the best CMO […]
The Hidden Cost That Nobody Puts in the Budget When a drug development team builds a plan for getting from lead candidate to Phase I, they typically account for formulation development costs, GMP manufacturing costs, analytical work, and regulatory fees. What rarely appears on the spreadsheet is the cost of moving data and processes between […]
Developing complex nanomedicines like lipid nanoparticles (LNPs) and polymeric micelles introduces unique challenges for traditional bioanalytical validation. In conventional small-molecule formulations, quantifying drug concentrations is a straightforward process of extraction and chromatographic resolution. However, within a nanomedicine matrix, the active pharmaceutical ingredient (API) exists in a dynamic equilibrium, partitioned between an encapsulated core and an […]
What Is the Difference Between a CMO and a CDMO? If you are building a drug, the partner you choose at the start of development will shape how quickly you get to the clinic, how clean your CMC package looks, and how many unexpected problems surface along the way. The difference between a Contract Manufacturing […]
For most small and mid-size biotech companies, getting to first-in-human (FIH) dosing as quickly as possible is an existential priority. Clinical data is the currency of biotech fundraising. Every month between selecting a candidate and dosing the first patient in a Phase I study is a month during which a competitor may be generating data, […]
The global validation of mRNA technology during the COVID-19 pandemic established lipid-encapsulated nucleic acids as a viable class of modern biopharmaceuticals. However, the molecular requirements for prophylactic vaccines represent only a fraction of the broader capabilities of mRNA therapeutics. In a vaccine application, the target payload simply needs to induce a brief, localized immune response […]
The successful transition of a complex nanomedicine from a laboratory process to a scalable, cGMP-compliant drug product requires overcoming severe fluid-dynamics and engineering constraints during downstream processing. While establishing absolute sterility is a non-negotiable mandate for all parenteral injectables, the physical properties of nano-sized drug products complicate standard industry protocols. Traditional sterilization methods, such as […]
Translating a nanomedicine candidate from successful preclinical proof-of-concept into a compliant clinical drug product requires early alignment with evolving regulatory expectations. Unlike conventional small molecules, nano-sized drug products present distinct biological and structural complexity. Their safety and therapeutic performance are governed not just by chemical composition, but by the physical architecture of the structured particle […]
The therapeutic potential of genetic medicine hinges entirely on the efficiency of intracellular delivery. While mRNA therapeutics have revolutionized fields ranging from oncology immunotherapy to rare disease interventions, their clinical translation is restricted by the biological fragility of nucleic acids. Unprotected mRNA molecules face immediate enzymatic degradation by extracellular RNases and possess a highly negative […]
In the evolving oncology landscape, the primary challenge remains the systemic toxicity and narrow therapeutic index of traditional chemotherapeutics. As molecules in the oncology pipeline become increasingly complex and often highly potent, the industry is shifting toward targeted nanomedicine to improve biodistribution. Nanomedicines offer a sophisticated solution by encapsulating these “hard-to-make” drugs within protective carriers, […]
The Critical Challenge: Maintaining Particle Size During Scale-Up The transition of Lipid Nanoparticles (LNPs) from a controlled laboratory environment to clinical-grade production is one of the most significant hurdles in modern drug delivery. While the industry has seen a surge in nucleic acid therapeutics, many promising candidates stall during the scale-up phase. The core challenge […]
In the modern oncology and rare disease landscape, the most promising therapeutic candidates—such as mRNA, siRNA, and high-potency APIs (HPAPIs)—often suffer from poor aqueous solubility or rapid systemic degradation. Lipid Nanoparticles (LNPs) have emerged as the gold standard for delivering these “hard-to-make” drugs, yet many programs stall during the transition from laboratory bench to clinical production. The […]
